This article is more than 5 years old. Information may no longer be current.
Maryland Proton Treatment Center appoints medical director
Click Here to Manage Email Alerts
Charles B. Simone II, MD, has been named medical director of the Maryland Proton Treatment Center.
Simone, who will begin his new role in November, will ensure the treatment center is integrated into the University of Maryland School of Medicine radiation oncology program and the University of Maryland Greenebaum Comprehensive Cancer Center.
He also will participate in the development of research protocols and clinical trials, as well as help refine criteria to determine which patients are most appropriate for proton therapy.
“Dr. Simone brings a wealth of knowledge and experience to this deeply important role,” E. Albert Reece, MD, PhD, MBA, dean of the school of medicine and vice president for medical affairs at University of Maryland, said in a press release. “He will be an essential asset to the Maryland Proton Treatment Center as it continues to grow and develop into one of the premier treatment and research centers in the world.”
Simone is recognized for his expertise in the use of proton therapy for the treatment of thoracic malignancies, as well as his research in thoracic radiation oncology. He previously served as co-director of the Penn Mesothelioma and Pleural Program at University of Pennsylvania Health System, as well as associate professor in the department of radiation oncology at University of Pennsylvania School of Medicine.
“I am very excited to work at this cutting-edge center,” Simone said in the press release. “Our goal will be to foster world-class treatment for cancers using proton therapy, as well as to further research in this area and educate outstanding researchers and clinicians.”